Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

43

Revenue 2017

Perjeta

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Perjeta was produced by Roche.

Roche faces biosimilar blitz in 2018

Roche faces biosimilar blitz in 2018 Last year, Ocrevus, Tecentriq, Perjeta and Alecensa sales drove a 5% growth for Roche, along with label extensions for existing products and approvals for new medicines Ocrevus and Hemlibra in the ... US. Schwan added: “I am particularly pleased with

Mylan gets first biosimilar Herceptin OK from FDA

Mylan gets first biosimilar Herceptin OK from FDA reduction in sales after the rivals launch, in part because use of the drug in combination with newer HER2 drug Perjeta (pertuzumab) is on the rise.

Ocrevus off to a flying start as Roche raises 2017 forecasts

Ocrevus off to a flying start as Roche raises 2017 forecasts Perjeta (pertuzumab) for breast cancer continued to grow - rising 17% to 1.07bn francs - and immunotherapy Actemra/RoActemra (tocilizumab) also put in a good showing, rising 13% to 922m francs thanks

NICE relents on Kadcyla after Roche pricing negotiations

NICE relents on Kadcyla after Roche pricing negotiations Breast Cancer Now delivered a warning about another Roche HER2 drug - Perjeta (pertuzumab) - which it said was at risk of being removed from NHS use as a first-line treatment for ... Perjeta's benefits are extraordinary, offering nearly 16 additional

Roche trumpets APHINITY data, but did it hit the mark?

Roche trumpets APHINITY data, but did it hit the mark? One year of adjuvant therapy with Perjeta plus Herceptin and chemotherapy can cost upwards of $150, 000, roughly twice the cost of Herceptin alone. ... A large chunk of Perjeta's $5bn sales forecast has been attributed to adjuvant use alongside Herceptin

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
dna Communications

Healthcare communications with unique thinking, insight and attitude...

Latest intelligence

The importance of co-creation with patients
Overcoming the barriers...
Three billboards on the road to multichannel
Chris Ross examines the trends driving multichannel communication in 2019...
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics